Health & Fitness
Wed, March 20, 2013Tue, March 19, 2013Mon, March 18, 2013Sun, March 17, 2013Fri, March 15, 2013Thu, March 14, 2013Wed, March 13, 2013Tue, March 12, 2013Mon, March 11, 2013Sun, March 10, 2013Sat, March 9, 2013Fri, March 8, 2013Thu, March 7, 2013Wed, March 6, 2013Tue, March 5, 2013Mon, March 4, 2013Sun, March 3, 2013Sat, March 2, 2013Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference
Published in Health and Fitness on Thursday, March 7th 2013 at 4:45 GMT by Market Wire
Uroplasty To Present At The 25th Annual ROTH Growth Stock Conference -- MINNEAPOLIS, March 7, 2013 /PRNewswire/ --
MINNEAPOLIS, March 7, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen , President and CEO, and Darin Hammers , Vice President of US Sales, will present the Company's business strategy and financial results at the 25th Annual ROTH Growth Stock Conference at 8:30 AM PT on Monday, March 18, 2013 at The Ritz Carlton in Dana Point, CA.
Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at [ http://wsw.com/webcast/roth27/upi/ ] or through Uroplasty's website at [ www.uroplasty.com ]. An archived replay of the presentation will be available for 90 days.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at [ www.uroplasty.com ].
For Further Information:
Uroplasty, Inc.
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, Treasurer
952-426-6140 |
EVC Group
Doug Sherk/Jenifer Kirtland (Investors), 415-568-9349
Amy Phillips (Media), 412-327-9499 |
SOURCE Uroplasty, Inc.
RELATED LINKS
[ http://www.uroplasty.com ]
